Metformin for Weight Loss vs GLP-1s: How Big Is the Gap?

Metformin has been used since the late 1950s, is on the World Health Organization’s essential medicines list, costs a few dollars a month, and is the single most commonly trialed off-label weight medication in American obesity clinics. In one Weill Cornell weight-management cohort, 88.3% of patients had tried metformin at some point [1].

It is also, for weight loss specifically, a fairly weak drug.

Both of those things are true at once, and the gap between them explains why this comparison confuses people.

What is metformin and why do people take it for weight?

Metformin is a biguanide approved by the FDA for type 2 diabetes. It reduces how much glucose your liver produces and improves how sensitively your body responds to insulin, largely through AMPK-dependent pathways and effects in the gut [2].

It is not approved for weight loss. Prescribing it for weight, prediabetes, PCOS or antipsychotic-associated weight gain is off-label. That is legal and extremely common, but it means there is no FDA-reviewed weight indication behind it.

People reach for it because it is cheap, because it has an exceptionally long safety record, because it does not cause weight gain the way many older diabetes drugs do, and because it is easy to get from a primary care provider who may be less comfortable prescribing an injectable.

How much weight does metformin cause you to lose?

The best data come from the Diabetes Prevention Program (DPP) and its long-term extension, the DPP Outcomes Study (DPPOS). This is one of the largest and longest randomized trials in the field.

In the DPP’s randomized phase, over 2.8 years:

Arm	Mean weight loss
Placebo	0.1 kg
Metformin	2.1 kg
Intensive lifestyle intervention	5.6 kg

Source: DPP Research Group [3].

Then it gets more interesting. In the long-term follow-up, averaged over the total follow-up period:

• Metformin group, regardless of adherence: 2.0% weight loss, or 1.9 kg from baseline [4]
• Among those highly adherent to metformin: 3.5%, or 3.1 kg [4]
• Among placebo participants, body weight stayed relatively stable but waist circumference increased after the fourth year [4]

Across the unblinded follow-up, weight loss remained significantly greater in the metformin group than placebo (2.0% versus 0.2%), and the degree of continuing adherence predicted the degree of weight loss [5]. The researchers’ conclusion was that metformin weight loss is related to adherence and is durable for at least 10 years of treatment [5].

Mean weight change at one year was −2.7 kg in the metformin group in DPP, against −1.52 kg (95% CI −2.82 to −0.21) in a separate meta-analysis of metformin trials [4].

So: roughly 2 to 3 kg, or 4 to 7 pounds, and it stays off for a decade if you keep taking it.

How does that compare to a GLP-1?

Drug	Trial	Duration	Mean weight loss
Metformin	DPP / DPPOS	2.8 years and 10-year follow-up	~2.0–2.1 kg (about 2%)
Semaglutide 2.4 mg	STEP 1	68 weeks	14.9%
Semaglutide 2.4 mg	SURMOUNT-5	72 weeks	13.7% (15.0 kg)
Tirzepatide	SURMOUNT-5	72 weeks	20.2% (22.8 kg)
Orforglipron 36 mg	ATTAIN-1	72 weeks	12.4%

Source: DPPOS [4][5]; Eli Lilly SURMOUNT-5 [6].

Metformin produces about one-seventh of what semaglutide produces and about one-tenth of what tirzepatide produces.

A review of long-term drug treatment for obesity summarized it this way: metformin “produces small sustained weight losses of about 2% relative to placebo,” with a good safety profile and long clinical experience, and its usefulness as monotherapy for obesity treatment is therefore limited [7].

That is the fair verdict. Not useless, but not in the same category.

So why do obesity clinics use it so much?

Three reasons, and none of them is “because it works as well as a GLP-1.”

It is nearly free. Generic metformin is one of the cheapest drugs in American pharmacy, typically a few dollars a month. At that price, a 2% effect has a very different cost-benefit calculation than it would at $400 a month.

It is exceptionally safe and durable. The DPPOS long-term safety analysis concluded metformin used for diabetes prevention is safe and well tolerated across a decade [5]. Very few drugs in this space have that kind of record.

It does real things besides weight. Metformin reduced progression to type 2 diabetes by 31% versus placebo in DPP, and in the 15-year DPPOS follow-up both lifestyle and metformin continued to reduce diabetes development. For a person with prediabetes, that is the actual clinical goal, and weight is a proxy.

There is also an interesting signal in the real-world data. In the Weill Cornell Comprehensive Weight Control Center cohort, metformin, topiramate and bupropion were each associated with increased odds of maintaining 10% or greater weight loss, with metformin used by 73.6% of patients at the final visit [1]. That is observational, and confounded by how these drugs get combined in practice, but it suggests metformin’s role may be more about supporting maintenance than driving initial loss.

Where does professional guidance put metformin?

Interestingly, not in the obesity pharmacotherapy chapter.

The Obesity Association’s 2026 “Pharmacologic Treatment of Obesity in Adults” standards frame drug selection around the weight reduction needed: 10% or more points to tirzepatide or semaglutide; 5% to 10% points to phentermine-topiramate; smaller targets can be met with naltrexone-bupropion, liraglutide, phentermine alone or orlistat [8]. Metformin does not appear in that hierarchy, because it is not an approved weight-management drug.

Where it does appear is in the American Diabetes Association’s diabetes standards, as a first-line agent for glycemic control and as a diabetes-prevention option in prediabetes [9].

That is the cleanest way to understand metformin’s place: it is a metabolic drug that happens to cause a little weight loss, not a weight-loss drug.

Metformin versus berberine, briefly

Because both get recommended as “cheap metformin alternatives,” it is worth noting the relationship.

A 2008 trial in Metabolism randomized 36 adults with newly diagnosed type 2 diabetes to berberine 500 mg three times daily or metformin 500 mg three times daily for three months. The hypoglycemic effect was similar, and berberine actually outperformed metformin on triglycerides and total cholesterol by week 13 [10].

That is a genuinely interesting result, and it is also a 36-person, 13-week pilot study against a drug with 60 years of outcome data and a known cardiovascular profile. Berberine’s weight effects are weaker still: pooled analyses find between zero and about 0.84 kg.

If the goal is glucose control, metformin has the vastly stronger evidence base. If the goal is weight, neither is doing much.

What are metformin’s side effects?

For most people, mild and manageable.

Common: diarrhea, nausea, abdominal discomfort, metallic taste. These are worse with immediate-release formulations and at the start of treatment, and often improve with the extended-release version and slower titration. In DPPOS, self-reported gastrointestinal problems were tracked across the full follow-up and did not escalate over time [4].

Long-term: vitamin B12 deficiency with prolonged use. The American Diabetes Association’s Standards of Care state that periodic measurement of vitamin B12 levels should be considered in people on long-term metformin, particularly those with anemia or peripheral neuropathy; whether and how often to test is a decision for your clinician, not a schedule to set yourself [9]. In DPP, average hemoglobin and hematocrit were slightly lower in the metformin group, with decreases occurring in the first year and no further change over time [5].

Rare but serious: lactic acidosis, largely confined to people with significant kidney impairment, and the reason metformin is dose-limited or avoided below certain kidney function thresholds.

Compared with the boxed warnings on Contrave and Zepbound, the topiramate pregnancy requirement on Qsymia, or the controlled-substance status of phentermine, metformin’s profile is notably benign.

Who should think about metformin for weight?

Metformin makes the most sense when:

• You have prediabetes. This is its strongest use case. The weight loss is a bonus; the 31% reduction in progression to diabetes is the point.
• You have PCOS or another insulin-resistant state. It is widely used off-label here, and the weight effect is one part of a broader metabolic rationale.
• You have gained weight on a medication that causes weight gain, such as some antipsychotics, where metformin has been studied as a mitigation strategy.
• Cost is absolute. At a few dollars a month, nothing else in this space competes.
• You are already taking it for diabetes and are wondering whether it is contributing. It probably is, by about 2%.

It makes less sense when:

• You need 10% or more weight reduction. It will not get you there.
• You are treating obesity itself as the primary target, where approved anti-obesity medications exist with 5 to 20 times the effect.

What about combining metformin with a GLP-1?

Millions of people already do, because metformin is first-line for type 2 diabetes and GLP-1s are added on top. That is standard diabetes care, not an experimental combination.

For weight specifically, some clinicians continue metformin alongside an anti-obesity medication or after stopping one. The evidence for that specific sequencing is limited, and it is a decision for your prescriber rather than something to arrange yourself.

The short version

Metformin produces about 2 kg of weight loss, or roughly 2% of body weight, and keeps it off for at least a decade if you keep taking it. It costs a few dollars a month and is one of the safest drugs in wide use.

Semaglutide produces about 15 kg. Tirzepatide produces about 23 kg.

Metformin is not a GLP-1 alternative. It is a metabolic drug with modest, durable weight effects and a strong case in prediabetes. If your goal is preventing diabetes, it is excellent value. If your goal is losing 15% of your body weight, it is the wrong tool.

This article summarizes what published trials, FDA-approved labeling and professional guidelines report. It is not medical advice and does not recommend any drug or dose. Follow your own prescription and the directions your prescriber and pharmacist give you. Off-label prescribing decisions belong to you and your healthcare provider.

Sources

1. NewYork-Presbyterian / Weill Cornell — Assessing long-term outcomes of anti-obesity medications: https://www.nyp.org/advances/article/diabetes-endocrinology/assessing-long-term-outcomes-of-anti-obesity-medications
2. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases: https://pmc.ncbi.nlm.nih.gov/articles/PMC5839379
3. DPP Research Group — Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC6829283
4. Bray GA et al., Diabetes Care 2012 — Long-term safety, tolerability, and weight loss associated with metformin in the DPPOS: https://pmc.ncbi.nlm.nih.gov/articles/PMC3308305
5. PubMed record, DPPOS long-term metformin safety and weight: https://pubmed.ncbi.nlm.nih.gov/22442396
6. Eli Lilly — SURMOUNT-5 complete results published in NEJM: https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy
7. Long-term drug treatment for obesity: a systematic and clinical review: https://pmc.ncbi.nlm.nih.gov/articles/PMC3928674
8. Obesity Association / ADA — Standards of Care in Overweight and Obesity: pharmacologic treatment, 2026: https://reference.medscape.com/cc2/p10/standards-care-overweight-obesity-ada-guidelines-2026a1000cjs
9. American Diabetes Association — Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes 2026: https://diabetesjournals.org/care/article/49/Supplement_1/S166/163915/8-Obesity-and-Weight-Management-for-the-Prevention
10. Yin J, Xing H, Ye J, Metabolism 2008 — Efficacy of berberine in patients with type 2 diabetes: https://pmc.ncbi.nlm.nih.gov/articles/PMC2410097
11. NovoCare Pharmacy (self-pay GLP-1 pricing): https://www.novocare.com/pharmacy.html